Log in

Log in


The HLH Steering Committee is responsible for charting strategic direction of the HS in their specified areas, including conduct of clinical trials and engagement with the broader group of investigators interested in HLH.


Scott Canna - Chair
Children's Hospital of Philadelphia - Philadelphia, PA USA
Term of Office: 2022 - 2026

Despina Moshous - Vice-Chair
Hopital Necker Enfants Malades - Paris, France
Term of Office: 2020 - 2024

Scott Baker
Fred Hutchinson Cancer Research Center - Seattle, WA USA
Term of Office: 2022-2026

Shanmuganathan Chandrakasan
Emory University, Children's Healthcare of Atlanta - Atlanta, GA USA
Term of Office: 2022 - 2026

Michael Jordan 
Cincinnati Children’s Hospital Medical Center – Cincinnati, OH, USA
Term of Office: 2021 - 2025

Kai Lehmberg
University Medical Center Hamburg-Eppendorf - Hamburg, Germany
Term of Office: 2021-2025 

Rafal Machowicz
Medical University of Warsaw - Warsaw, Poland
Term of Office: 2023 - 2027

Elena Sieni
A. Meyer Children's University Hospital - Florence, Italy
Term of Office: 2023 - 2027

Zhao Wang
Beijing Friendship Hospital, Capital Medical University - Beijing, China
Term of Office: 2023 - 2027

Takahiro Yasumi
Kyoto University Graduate School of Medicine - Kyoto, Japan
Term of Office: 2020 - 2024 


Current Projects

    The HLH Steering Committee is focused on facilitating and supporting research and clinical care improvement efforts in the field of HLH and other related hyperinflammatory diseases and process areas.  We appreciate the need for clinical trials to obtain rigorous data and the challenges of performing clinical trials due to lack of funds to support clinical trial infrastructure and achieve regulatory compliance at an international level. We believe that the Histiocyte Society HLH Steering Committee can serve an important role in synergizing efforts amongst different institutional, regional, and national groups. We are currently focused on three key activities:  

  1. Developing an HLH grading/staging system to harmonize descriptions of clinical HLH severity amongst various research and clinical trial efforts.   
  2. Developing a common HLH diagnostic algorithm, informed by committee member institutional pathways, to be made freely available on the Histiocyte Society website.    
  3. Supporting new and ongoing research being conducted by Histiocyte Society members and by other clinical societies. 

Please reach out if you are interested in participating in either of the first 2 activities or if you would like support (non-financial) of any study efforts: or  

Key questionsin our field: 

  •  How do we maximize accurate and timely diagnosis of HLH and its underlying causes while minimizing harm from incomplete or misdiagnoses?  
  •  How do we grade/stage HLH severity to help with communication and clinical trial consistency? 
  •  What is the optimal front-line therapy of HLH? 
  •  How do we improve access to newer lab tests and treatments? 
  •  What is the next step in improving allogeneic hematopoietic cell transplant outcomes? 

Office: +1 (856) 589-6606
Fax: +1 (856) 589-6614

Histiocyte Society
332 N Broadway
Pitman, NJ 08071 USA

Powered by Wild Apricot Membership Software